Followers | 58 |
Posts | 1635 |
Boards Moderated | 0 |
Alias Born | 11/14/2012 |
Tuesday, February 02, 2016 11:51:38 PM
Editas Medicine, Inc., a leading genome editing company, today announced the pricing of its initial public offering of 5,900,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares are being offered by Editas Medicine. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 885,000 shares of common stock from Editas Medicine at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The company’s common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading on Wednesday, February 3, 2016 under the ticker symbol “EDIT.”
Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager, and JMP Securities is acting as co-manager for the offering.
Recent EDIT News
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 05/10/2024 10:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:21:43 PM
- U.S. Futures Slightly Dip Amid Corporate Earnings and Quiet Economic Calendar, Oil Prices Fall • IH Market News • 05/08/2024 12:29:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:08:48 AM
- Editas Medicine Announces First Quarter 2024 Results and Business Updates • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 04/22/2024 08:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:06:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:03:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:54:42 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:58:52 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/28/2024 10:13:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/28/2024 09:39:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:06:57 PM
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:40:25 PM
- Editas Medicine to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 01/31/2024 02:00:00 PM
- Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 01:15:00 PM
- Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update • Dow Jones News • 12/13/2023 05:48:00 PM
- Editas Medicine Strikes License Deal With Vertex Pharmaceuticals • Dow Jones News • 12/13/2023 02:49:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:02:25 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM